BRKR Stock Analysis: Bruker | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 8.160m USD | 12M Return: 83.3% | US1167941087 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 108M
EPS Trend: -93.9%
Qual. Beats: 2
Rev. Trend: 92.1%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bruker Corporation is a U.S.-based manufacturer of scientific instruments and analytical and diagnostic solutions, organized into four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. Its product portfolio spans magnetic resonance spectroscopy (NMR and EPR), mass spectrometry, molecular diagnostics kits, X-ray and fluorescence instrumentation, atomic force microscopy, optical fluorescence microscopy, and superconducting materials and wires, supported by service, lifecycle, and lab automation offerings. The company was founded in 1960 and is headquartered in Billerica, Massachusetts, and trades on NASDAQ under the ticker BRKR.
The company sits in the Life Sciences Tools & Services sub-industry within Health Care, supplying research, analytical, and process instruments primarily to pharmaceutical, biotechnology, academic, government, and industrial customers. Its business model combines capital equipment sales with recurring revenue from consumables, aftermarket services, and lifecycle support tied to its installed base of advanced analytical systems.
- Nano segment growth driven by semiconductor metrology demand
- Biopharma and proteomics demand supports BioSpin and CALID revenue
- China weakness and FX headwinds pressure reported organic growth
| Net Income: -71.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.77 > 1.0 |
| NWC/Revenue: 29.15% < 20% (prev 23.68%; Δ 5.47% < -1%) |
| CFO/TA 0.03 > 3% & CFO 190.4m > Net Income -71.2m |
| Net Debt (1.90b) to EBITDA (247.7m): 7.69 < 3 |
| Current Ratio: 1.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (152.2m) vs 12m ago 0.33% < -2% |
| Gross Margin: 46.69% > 18% (prev 48.25%; Δ -1.56% > 0.5%) |
| Asset Turnover: 56.48% > 50% (prev 54.30%; Δ 2.17% > 0%) |
| Interest Coverage Ratio: 0.29 > 6 (EBIT TTM 17.6m / Interest Expense TTM 61.5m) |
| A: 0.17 (Total Current Assets 2.23b - Total Current Liabilities 1.20b) / Total Assets 6.05b |
| B: 0.38 (Retained Earnings 2.29b / Total Assets 6.05b) |
| C: 0.00 (EBIT TTM 17.6m / Avg Total Assets 6.20b) |
| D: 0.66 (Book Value of Equity 2.40b / Total Liabilities 3.63b) |
| Altman-Z'' = 3.05 = A |
| DSRI: 1.17 (Receivables 875.4m/738.7m, Revenue 3.50b/3.44b) |
| GMI: 1.03 (GM 48.25% / 46.69%) |
| AQI: 0.95 (AQ_t 0.51 / AQ_t-1 0.54) |
| SGI: 1.02 (Revenue 3.50b / 3.44b) |
| TATA: -0.04 (NI -71.2m - CFO 190.4m) / TA 6.05b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of September 18, 2026, the stock is trading at USD 60.67 with a total of 4,105,637 shares traded. Over the past week, the price has changed by +11.46%, over one month by +5.20%, over three months by +8.82% and over the past year by +83.32%.
Current recommended Stop Loss: 56.80 (which is 6.4% or 1.4 ATR below the current price).
Bruker has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy BRKR.
- StrongBuy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 59.2 | -2.4% |
P/E Forward = 15.2207
P/S = 2.3318
P/B = 3.4824
P/EG = 1.5155
Revenue TTM = 3.50b USD
EBIT TTM = 17.6m USD
EBITDA TTM = 247.7m USD
Long Term Debt = 1.81b USD (from longTermDebt, last quarter)
Short Term Debt = 101.0m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.8m
Net Debt = 1.90b USD (calculated: Debt 2.09b - CCE 184.9m)
Enterprise Value = 10.1b USD (8.16b + Debt 2.09b - CCE 184.9m)
Interest Coverage Ratio = 0.29 (Ebit TTM 17.6m / Interest Expense TTM 61.5m)
EV/FCF = 107.2x (Enterprise Value 10.1b / FCF TTM 93.9m)
FCF Yield = 0.93% (FCF TTM 93.9m / Enterprise Value 10.1b)
FCF Margin = 2.68% (FCF TTM 93.9m / Revenue TTM 3.50b)
Net Margin = -2.03% (Net Income TTM -71.2m / Revenue TTM 3.50b)
Gross Margin = 46.69% ((Revenue TTM 3.50b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 49.61% (prev 47.28%)
Tobins Q-Ratio = 1.66 (Enterprise Value 10.1b / Total Assets 6.05b)
Interest Expense / Debt = 2.94% (Interest Expense 61.5m / Debt 2.09b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 13.9m (EBIT 17.6m * (1 - 21.00%))
Current Ratio = 1.85 (Total Current Assets 2.23b / Total Current Liabilities 1.20b)
Debt / Equity = 0.87 (Debt 2.09b / totalStockholderEquity, last quarter 2.40b)
Debt / EBITDA = 7.69 (Net Debt 1.90b / EBITDA 247.7m)
Debt / FCF = 20.28 (Net Debt 1.90b / FCF TTM 93.9m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.15% (Net Income -71.2m / Total Assets 6.05b)
RoE = -2.92% (Net Income TTM -71.2m / Total Stockholder Equity 2.43b)
RoCE = 0.41% (EBIT 17.6m / Capital Employed (Equity 2.43b + L.T.Debt 1.81b))
RoIC = 0.29% (NOPAT 13.9m / Invested Capital 4.77b)
WACC = 8.40% (E(8.16b)/V(10.2b) * Re(9.95%) + D(2.09b)/V(10.2b) * Rd(2.94%) * (1-Tc(0.21)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.52 | Cagr: 1.90%
[DCF] Terminal Value 77.82% ; FCFF base≈76.1m ; Y1≈87.2m ; Y5≈128.3m
[DCF] Fair Price = 0.07 (EV 1.92b - Net Debt 1.90b = Equity 11.1m / Shares 152.4m; r=8.40% [WACC]; 5y FCF grow 15.0% → 2.50% )
[DCF] Fair Price = 0.07 (out of range, set to none)
EPS Correlation: -93.85 | EPS CAGR: -14.61% | SUE: 1.52 | # QB: 2
Revenue Correlation: 92.10 | Revenue CAGR: 7.86% | SUE: -1.12 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.42 | Chg30d=+0.57% | Revisions=-79% | Analysts=13
EPS current Year (2026-12-31): EPS=2.12 | Chg30d=+0.04% | Revisions=+0% | GrowthEPS=+16.0% | GrowthRev=+3.5%
EPS next Year (2027-12-31): EPS=2.39 | Chg30d=-0.70% | Revisions=-36% | GrowthEPS=+12.6% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -46% (up=8, down=24)